KDM5D predicts response to docetaxel chemotherapy in metastatic castration resistant prostate cancer patients

BACKGROUND: The administration of docetaxel chemotherapy is one therapeutic option to delay disease progression and increase overall survival in metastatic castration resistant prostate cancer (mCRPC). However, about 15% of patients are primary resistant to chemotherapy and hence would benefit from...

Descripción completa

Detalles Bibliográficos
Autores principales: Schäfer, Georg, Bednarova, Nikola, Heidenreich, Axel, Klocker, Helmut, Heidegger, Isabel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Original Article on Management of Advanced Genitourinary Malignancies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8575572/
https://www.ncbi.nlm.nih.gov/pubmed/34804837
http://dx.doi.org/10.21037/tau-20-1084

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8575572/
https://www.ncbi.nlm.nih.gov/pubmed/34804837
http://dx.doi.org/10.21037/tau-20-1084

Ejemplares similares